FDA Approves Daraxonrasib for Pancreatic Cancer Treatment

The US Food and Drug Administration granted historic approval on August 26 to daraxonrasib (Rasonque), establishing it as a first-in-class targeted therapy for the most common form of pancreatic cancer. The agency approved this daily oral medication for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic treatment. The decision brings a highly anticipated, chemotherapy-free targeted option to a patient population historically limited by a lack of effective therapeutic interventions, arriving 6.5 months ahead of schedule.

Acting FDA Commissioner Kyle Diamantas, JD, emphasized the approval’s significance in the agency’s press release.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” Diamantas stated. “I am immensely proud of the dedicated FDA scientists whose fast, thorough review and relentless commitment made this groundbreaking milestone a reality.”

According to the National Cancer Institute, pancreatic adenocarcinoma accounts for approximately 90% to 95% of the 67,000 new pancreatic cancer cases diagnosed in the United States annually. Despite representing roughly 3.2% of all cancer diagnoses, it carries a disproportionately high share of overall cancer deaths. This disparity stems largely from typically late detection, an aggressive disease course, and a historical shortage of targeted therapies.

Unprecedented Clinical Benefit in Randomized Trial

The FDA based its approval on results from the RASolute 302 trial, a randomized, open-label, multicenter clinical study involving adults with metastatic pancreatic ductal adenocarcinoma who had received one prior fluoropyrimidine- or gemcitabine-based regimen for metastatic disease. In this trial, daraxonrasib demonstrated unprecedented clinical benefit, doubling median overall survival to 13.2 months compared to just 6.7 months for patients receiving standard chemotherapy. The results drew cheers when presented at the 2026 American Society of Clinical Oncology annual meeting.

Patients enrolled in the study received either oral daraxonrasib at 300 mg daily or the investigator’s choice of standard chemotherapy. The trial demonstrated improvements in overall survival in patients with the RAS G12 mutation as well as in the overall population, regardless of mutation status. Based on these findings, the new approval does not require the presence of a known RAS mutation for treatment eligibility.

Angelo de Claro, MD, director of the FDA’s Oncology Center of Excellence, highlighted the drug’s remarkable performance in his statement.

“This drug showed unprecedented results in an area of high unmet need,” de Claro said. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions.”

Novel Mechanism Targets Key Cancer Driver

Daraxonrasib represents a novel pharmacological class as a once-daily oral tablet therapy that acts as a multi-form RAS inhibitor. The drug is engineered to target multiple forms of the RAS protein, which acts as a key molecular driver of tumor growth in most patients with pancreatic adenocarcinoma. Brian M. Wolpin, MD, MPH, director of the Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute in Boston, noted during the ASCO presentation that 90% of pancreatic ductal adenocarcinoma tumors carry RAS driver mutations.

Daraxonrasib functions as an oral, potent inhibitor of the RAS(ON) state across multiple RAS variants and wild-type RAS. By directly binding to and inhibiting these aberrant proteins, the medication blocks downstream signaling pathways that promote malignant cellular proliferation and survival. This targeted approach represents a significant departure from traditional cytotoxic chemotherapy approaches that have dominated pancreatic cancer treatment for decades.

Progression-Free Survival and Response Rates

The median progression-free survival by blinded independent central review reached 7.3 months with daraxonrasib versus 3.5 months with chemotherapy in the RAS G12-mutant population, demonstrating a hazard ratio of 0.45. In the overall population, progression-free survival measured 7.2 months versus 3.6 months, respectively, with a hazard ratio of 0.49. These results represent a near-doubling of the time patients lived without disease progression.

The confirmed objective response rate favored daraxonrasib over chemotherapy in the RAS G12-mutant population at 33.2% versus 11.8%, a statistically significant difference. In the overall population, response rates reached 31.6% for daraxonrasib compared to 11.2% for chemotherapy, both differences achieving statistical significance. These response rates indicate a tripling of the proportion of patients whose tumors shrank meaningfully on treatment.

Improved Quality of Life Measures

Daraxonrasib also significantly delayed time to deterioration in cancer-related pain, extending this measure to 9.2 months versus 3.8 months with chemotherapy, achieving a hazard ratio of 0.51. The drug similarly delayed deterioration in global quality of life measures, addressing a critical concern for patients facing this aggressive malignancy. These patient-centered outcomes demonstrate that the survival benefit translates into meaningful improvements in how patients feel during treatment.

The safety profile of daraxonrasib proved remarkably favorable compared to standard chemotherapy. Adverse events leading to treatment discontinuation occurred in only 1.2% of patients receiving daraxonrasib versus 11.2% of those on chemotherapy. This nearly tenfold difference in discontinuation rates suggests patients tolerate the oral targeted therapy substantially better than intravenous cytotoxic chemotherapy regimens.

Expedited Review Process

The application underwent review under the FDA Commissioner’s National Priority Voucher pilot program, which the agency established to accelerate development and review of treatments addressing critical unmet medical needs. The 6.5-month acceleration of the approval timeline underscores both the strength of the clinical data and the urgent need for effective therapies in this patient population. This expedited approval process ensures patients gain access to this breakthrough therapy months earlier than standard timelines would allow.

The approval of daraxonrasib marks a transformative moment for patients with metastatic pancreatic ductal adenocarcinoma, a disease that has resisted meaningful therapeutic advances for decades. By targeting the fundamental molecular drivers of tumor growth rather than using broad cytotoxic approaches, this first-in-class oral therapy offers both improved survival and better quality of life. The medication’s arrival months ahead of schedule reflects regulatory recognition of its exceptional clinical benefit in one of oncology’s most challenging disease settings.